Richard W. Roberts

Richard W. Roberts

Auto-generated profile, based on publicly available information

Richard W. Roberts

Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA, 90089, USA.

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Neuron
Verified
Journal Article
Closed access
GGGarrett G. Gross
Garrett G. Gross
JJJason Junge
Jason Junge
RMRudy J. Mora
Rudy J. Mora
HKHyung-Bae Kwon
Hyung-Bae Kwon
COC. Anders Olson
C. Anders Olson
DADon B. Arnold
Don B. Arnold

1 September 2007 in ACS Chemical Biology
Verified
Journal Article
Closed access
SMSteven W. Millward
Steven W. Millward
SFStephen Fiacco
Stephen Fiacco
RARyan J. Austin
Ryan J. Austin
RRRichard W. Roberts
Richard W. Roberts

24 June 2021 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
GKGolnaz Kamalinia
Golnaz Kamalinia
BGBrian J. Grindel
Brian J. Grindel
TTTerry T. Takahashi
Terry T. Takahashi
SMSteven Wesley Millward
Steven Wesley Millward
RRRichard W. Roberts
Richard W. Roberts
In this review, Kamalinia et al. discuss mRNA display and its role in peptide and protein design.

19 September 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SHShannon M. Howell
Shannon M. Howell
SFStephen V. Fiacco
Stephen V. Fiacco
TTTerry T. Takahashi
Terry T. Takahashi
FJFarzad Jalali-Yazdi
Farzad Jalali-Yazdi
SMSteven W. Millward
Steven W. Millward
RRRichard W. Roberts
Richard W. Roberts
Peptides constructed with the 20 natural amino acids are generally considered to have little therapeutic potential because they are unstable in the presence of proteases and peptidases. However, proteolysis cleavage can be idiosyncratic, and it is possible that natural analogues of functional sequences exist that are highly resistant to cleavage. Here, we explored this idea in the context of peptides that bind to the signaling protein Gαi1. To do this, we used a two-step in vitro selection process to simultaneously select for protease resistance while retaining function–first by degrading the starting library with protease (chymotrypsin), followed by positive selection for binding via mRNA display. Starting from a pool of functional sequences, these experiments revealed peptides with 100–400 fold increases in protease resistance compared to the parental library. Surprisingly, selection for chymotrypsin resistance also resulted in similarly improved stability in human serum (~100 fold). Mechanistically, the decreases in cleavage results from both a lower rate of cleavage (kcat) and a weaker interaction with the protease (Km). Overall, our results demonstrate that the hydrolytic stability of functional, natural peptide sequences can be improved by two orders of magnitude simply by optimizing the primary sequence.

10 May 2019 in ACS Central Science
Verified
Journal Article
Open access
MLMorgan B. Ludwicki
Morgan B. Ludwicki
JLJiahe Li
Jiahe Li
ESErin A. Stephens
Erin A. Stephens
RRRichard W. Roberts
Richard W. Roberts
SKShohei Koide
Shohei Koide
Matthew Peter DeLisaMatthew Peter DeLisa
Matthew Peter DeLisa
Manipulation of the ubiquitin-proteasome pathway to achieve targeted silencing of cellular proteins has emerged as a reliable and customizable strategy for remodeling the mammalian proteome. One such approach involves engineering bifunctional proteins called ubiquibodies that are comprised of a synthetic binding protein fused to an E3 ubiquitin ligase, thus enabling post-translational ubiquitination and degradation of a target protein independent of its function. Here, we have designed a panel of new ubiquibodies based on E3 ubiquitin ligase mimics from bacterial pathogens that are capable of effectively interfacing with the mammalian proteasomal degradation machinery for selective removal of proteins of interest. One of these, the Shigella flexneri effector protein IpaH9.8 fused to a fibronectin type III (FN3) monobody that specifically recognizes green fluorescent protein (GFP), was observed to potently eliminate GFP and its spectral derivatives as well as 15 different FP-tagged mammalian proteins that varied in size (27–179 kDa) and subcellular localization (cytoplasm, nucleus, membrane-associated, and transmembrane). To demonstrate therapeutically relevant delivery of ubiquibodies, we leveraged a bioinspired molecular assembly method whereby synthetic mRNA encoding the GFP-specific ubiquibody was coassembled with poly A binding proteins and packaged into nanosized complexes using biocompatible, structurally defined polypolypeptides bearing cationic amine side groups. The resulting nanoplexes delivered ubiquibody mRNA in a manner that caused efficient target depletion in cultured mammalian cells stably expressing GFP as well as in transgenic mice expressing GFP ubiquitously. Overall, our results suggest that IpaH9.8-based ubiquibodies are a highly modular proteome editing technology with the potential for pharmacologically modulating disease-causing proteins.

1 July 2008 in ACS Chemical Biology
Verified
Journal Article
Closed access
COC. Anders Olson
C. Anders Olson
HLHsiang-I Liao
Hsiang-I Liao
RSRen Sun
Ren Sun
RRRichard W. Roberts
Richard W. Roberts